In contrast to atezolizumab or durvalumab, ipilimumab (an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody) in combination with chemotherapy prolongs PFS, but does not improve OS in treatment-naïve ES-SCLC [41]. The gene discussed is CTLA4; the disease is small cell lung carcinoma.